Breast and Prostate Cancer Genetic Detection Tests (10008 & 10012)
- 詳細技術說明
- Key Benefit: Use of specific genetic biomarkers to determine a person's risk of developing prostate or breast cancer.
- *Abstract
-
The University of Louisville is seeking a business partnerinterested in commercializing gene biomarker technologies to predetermine a person’spropensity to develop breast or prostate cancer. Recent advances demonstrate a relationshipbetween chronic/recurrent inflammation and complex diseases. In breast cancer, it has been suggested thatchronic or recurrent inflammation attributed to persistent exposure topathogens may alter the tissue micro-environment that favors tumor growth. These and other observations provided thebasis for UofL’s discovery of personalized genetic biomarkers that willdetermine a patient’s risk of developing cancer. The University of Louisville’s new technologiesbased on genetic variants will empower patients and their doctors to makebetter healthcare and lifestyle decisions.
ADVANTAGES
■ Uniquetests to determine an individual’s risk for developing breast/prostate cancer.
■ Personalizedtests to predict aggressive cancer, recurrent disease, and overall survival.
MARKET APPLICATIONS
■ Genebiomarker tests to determine an individual’s susceptibility to breast or prostatecancer.
■ Developmentof Diagnostic Kits to assess personalized cancer risk.
TECHNOLOGY
The present technologies arebased in part on the discovery of the role of the innate immune system incancer etiology. The tests provideprognostic and diagnostic panels of single nucleotide polymorphism (SNP)biomarkers for breast and prostate cancers. Inheritance of certain SNP’s and allele patterns (sequence variants) indicateincreased prostate or breast cancer risk. Initial validation studies of the biomarkers wereperformed at the University of Louisville by Dr. LaCreis R. Kidd, incollaboration with Dr. Kevin Kimbro at the Winship Cancer Institute of EmoryUniversity School of Medicine. Representative clinical papers are profiled in this abstract: Angiogenesis-associated sequence variantsrelative to breast cancer recurrence and survival published in CancerCauses Control, 23 June 2010; and Interaction among variant vascularendothelial growth factor (VEGF) and its receptor in relation to prostatecancer risk published in The Prostate Volume 70, 1 March 2010. Additional background references areavailable.
INTELLECTUAL PROPERTY
Predictive biomarker testtechnologies are protected by two patent application families.
CONTACT
For additionalinformation, or to discuss sponsored or collaborative research and developmentopportunities, please contact Holly Symonds Clark at the Office of TechnologyTransfer:
Telephone:(502) 852-2965
Email:holly.symonds.clark@louisville.edu
Website:http://louisville.edu/thinker
ReferenceDisclosure Refs. #10008 and #10012
LACREIS KIDD, Ph.D., MPH
Assistant Professor ofPharmacology and
Toxicology, University ofLouisville;
Joint Appointment as AssociateScientist,
James Graham Brown Cancer Center,
And Department of Epidemiology, Schoolof
Public Health & InformationSciencesSYNOPSIS
Dr.Kidd currently holds the Cancer Center’s “Our Highest Potential” Chair inCancer Research Endowment. In 2001, shewas awarded a post-doctoral fellowship through the National Cancer Institute(NCI) Cancer Prevention & Control Program, which allowed her to earn aMaster’s of Public Health degree in epidemiology and biostatistics at the JohnsHopkins Bloomberg School of Public Health (JHBSPH). She also received extensive training in thefield of genetic epidemiology at NCI and the Howard University Cancer Center.
RESEARCHINTERESTS
Dr.Kidd’s research seeks to identify, evaluate and validate complex gene-geneinteractions that may serve as effective predictors of prostate cancerdetection, prognosis, and clinical response/survival following therapeutictreatments in ethnically diverse sub-groups. Ultimately, her goal is to design a “SNP panel” to help clinicianspredict individuals who are likely to develop aggressive disease and/or respondfavorably to aggressive treatment based on a patient’s genetic signature. Her research involves advanced statistics andin silico tools to screen thousands of genetic mutations for their capacity topredict disease outcomes, followed by validation of targets using machinelearning algorithms.
RESEARCH AWARDS
· Servedas a principle investigator of a NCI Cancer Prevention grant as well as ahighly competitive and prestigious Prostate Cancer Foundation Award.
· Activemember of the men of African Descent and the Afro-Caribbean Prostate CancerConsortiums that seek to overcome sample size issues that often plaque geneticepidemiology studies through pooled analyses.
· Receivednumerous awards including special recognition to Eliminate Cancer HealthDisparities Among African-Americans, sponsored by the KentuckyAfrican-Americans Against Cancer (KAAC) and the National Black LeadershipInitiative on Cancer.
· Authoredseveral peer-reviewed journal articles/book chapter and abstracts.
· Mentorednumerous pre- and post-doctorate trainees who have received special recognitionat local and national scientific meetings.
EDUCATION/TRAINING
· Post-Doc,NIH, Cancer Prevention, 2001-2004
· Post-DocTrainee, NIEHS/NIH, Environmental Health, 1997-2000
· MPH,Johns Hopkins Bloomberg School of Public Health, Epidemiology/Biostatistics,2001
· Ph.D.,Massachusetts Institute of Technology, Toxicology, 1997
· B.S.,Spelman College, Biology/Pre-Medicine, 1990
· VassarCollege, Student Exchange program, Poughkeepsie, NY 1987
RESEARCH AND PROFESSIONAL EXPERIENCE
· 2004-present
Assistant Professor, Department of Pharmacology & Toxicology, University ofLouisville, KY· 2004-present
Associate member, James Graham Brown Cancer Center, University of Louisville,KY· 2004-present
Brown Endowed Assistant Professor in Health Disparities, University ofLouisville, KY· 2001-2004 Post-Doctorate Fellow, NCI Cancer PreventionFellowship Program, Cancer Prevention Studies Branch (CPSB), NCI/CCR, Bethesda,MA
· 2002
Summer Cancer Genetics Trainee, National Human Genome Center
Howard University Cancer Center, Washington, DC· 1997-2000 post-Doctorate Trainee, Johns Hopkins,Bloomberg School of Public Health, Baltimore, MD
· 1995-1997
NIEHS Pre-doctoral Trainee, Massachusetts Institute of Technology, Division ofToxicology, Cambridge, MA· 1990-1995
Pre-doctoral Fellow, National Institute of Health/Minority Access to ResearchCareers, Massachusetts Institute of Technology, Cambridge, MA· 1990
Summer Science Research Program Intern, Massachusetts Institute of Technology,Cambridge, MAPUBLICATIONS RELATED TO THIS INVENTION
VanCleave TT, Moore JH, BenfordML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW Jr, Kittles RA, Kidd, LC Interaction Among Variant VascularEndothelial Growth Factor (VEGF) and its receptor in relation to ProstateCancer Risk. The Prostate May 4, 2009, Volume70, Issue 4, pages 341-352, 1 March 2010.
LaCreisR. Kidd, Guy N.Brock, Tiva T. VanCleave, Marnita L. Benford, Nicole A. Lavender, Traci L. Kruer,James L. Wittliff, Angiogenesis-associatedsequence variants relative to breast cancer recurrence and survival, E-publicationahead of print, Cancer CausesControl, Received: 10 November2009/Accepted: 13 May 2010, SpringerScience Business Media B.V. 2010.
- 國家/地區
- 美國
